Precision in Care: Diagnosing and Evaluating Aplastic Anemia for Stem Cell Therapy
Diagnosing aplastic anemia is a complex process that goes beyond a simple blood test. Because the symptoms—such as persistent fatigue, frequent infections, and easy bruising—can mimic other conditions, a rigorous evaluation is critical. Accurate diagnosis is the cornerstone of effective treatment, determining whether a patient requires supportive care, immunosuppression, or a life-saving stem cell transplant.
The Diagnostic Journey
The process typically begins with a Complete Blood Count (CBC) to identify low levels of red blood cells, white blood cells, and platelets. However, the definitive diagnosis requires a bone marrow biopsy and aspiration. In this procedure, a small sample of bone marrow is examined to assess cellularity—the ratio of blood-forming cells to fat cells. In aplastic anemia, the marrow appears “empty” or hypocellular.
To understand the full scope of these tests and how severity is classified (from non-severe to very severe), it is essential to review the clinical criteria for Stem Cell Aplastic Anemia Diagnosis and Evaluation. This detailed evaluation not only confirms the disease but also rules out other potential causes such as myelodysplastic syndromes or paroxysmal nocturnal hemoglobinuria (PNH).
Advanced Evaluation at Liv Hospital
Once the diagnosis is confirmed, the evaluation shifts toward treatment planning. This includes Human Leukocyte Antigen (HLA) typing to identify potential stem cell donors, as well as screening for viral infections and assessing organ function to ensure the patient can tolerate the procedure.
At Liv Hospital, this evaluation is conducted by a multidisciplinary team of hematologists and pathologists using state-of-the-art diagnostic technology. The hospital’s focus is on speed and accuracy, ensuring that the time between diagnosis and the start of curative therapy is minimized to improve patient outcomes.
